Prabha N. Ibrahim

Biochemistry, Genetics and Molecular Biology · Life Sciences

19h-index7.7kcitations63works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Phosphodiesterase function and regulation(16), Synthesis and Catalytic Reactions(13), Melanoma and MAPK Pathways(9), Protein Degradation and Inhibitors(8), Cancer Mechanisms and Therapy(6)

Publications63 total

Supplementary Figures & Tables from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Tables 1 - 6, Figures 1 - 7 from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Methods from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Supplementary Methods from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Data from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Tables 1 - 6, Figures 1 - 7 from Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
2023Open Access
Supplementary Figures & Tables from BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
2023Open Access
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors
JAMA Oncology·2021· 38 citedOpen Access
Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model
Nature Communications·2019· 900 citedOpen Access
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
Cancer Discovery·2018· 135 citedOpen Access
Abstract 4711: Broad anti-tumor activity of a novel BET bromodomain inhibitor
Cancer Research·2016
RAF inhibitors that evade paradoxical MAPK pathway activation
Nature·2015· 374 cited
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor
New England Journal of Medicine·2015· 571 cited
Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 “Gatekeeper” F691L Mutation with PLX3397
Cancer Discovery·2015· 197 citedOpen Access
Discovery and Development of Vemurafenib: First‐in‐Class Inhibitor of Mutant BRAF for the Treatment of Cancer
Methods and principles in medicinal chemistry·2013
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor
Proceedings of the National Academy of Sciences·2013· 95 citedOpen Access
Case History
Annual reports in medicinal chemistry·2013· 4 cited
page 1 of 4Next →

Frequent Co-authors

Gideon Bollag(35), Gaston Habets(19), Jiazhong Zhang(18), Ben Powell(17), Wayne Spevak(16), Rafe Shellooe(16), Daniel W. Fong(16), Garson Tsang(15), Adhirai Marimuthu(14), S. Gillette(14), Brian L. West(13), Joseph Schlessinger(13), B.P. England(13), G.L. Card(12), Michael V. Milburn(12), Heidi Carias(12), David Artis(11), Elizabeth A. Burton(10), Catherine A. Luu(10), Marika Nespi(10)